Scientists test 'Living Drug' to reset immune system in devastating autoimmune diseases
NCT ID NCT06544330
Summary
This is an early-stage safety study testing a new two-part cell therapy for people with severe autoimmune diseases like lupus and scleroderma that haven't responded to other treatments. Doctors will collect a patient's own immune cells, genetically modify them to target a specific protein (CD19), and infuse them back, followed by a supporting drug (STK-009). The main goal is to see if this combination is safe and tolerable, while also checking if it helps control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Feinstein Institutes for Medical Research
Manhasset, New York, 11030, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
Ohio State University Wexner Medical Center
Columbus, Ohio, 43210, United States
-
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
Conditions
Explore the condition pages connected to this study.